The Prognostic Hub Gene POLE2 Promotes BLCA Cell Growth Via the PI3K/AKT Signaling Pathway

Overview

Journal Comb Chem High Throughput Screen

Publisher Bentham Science Publishers

Specialty Chemistry

Date 2024 Jul 4

PMID 38963027

Authors

Dongzhen Jiang

Huawei Zhang

Bingde Yin

MinKe He

Xuwei Lu

Chang He

Affiliations

Soon will be listed here.

Abstract

Background: BLCA is a common urothelial malignancy characterized by a high recurrence rate. Despite its prevalence, the molecular mechanisms underlying its development remain unclear.

Aims: This study aimed to explore new prognostic biomarkers and investigate the underlying mechanism of bladder cancer (BLCA).

Objective: The objective of this study is to identify key prognostic biomarkers for BLCA and to elucidate their roles in the disease.

Methods: We first collected the overlapping DEGs from GSE42089 and TCGA-BLCA samples for the subsequent weighted gene co-expression network analysis (WGCNA) to find a key module. Then, key module genes were analyzed by the MCODE algorithm, prognostic risk model, expression and immunohistochemical staining to identify the prognostic hub gene. Finally, the hub gene was subjected to clinical feature analysis, as well as cellular function assays.

Results: In WGCNA on 1037 overlapping genes, the blue module was the key module. After a series of bioinformatics analyses, POLE2 was identified as a prognostic hub gene in BLCA from potential genes (TROAP, POLE2, ANLN, and E2F8). POLE2 level was increased in BLCA and related to different clinical features of BLCA patients. Cellular assays showed that si-POLE2 inhibited BLCA proliferation, and si-POLE2+ 740Y-P in BLCA cells up-regulated the PI3K and AKT protein levels.

Conclusion: In conclusion, POLE2 was identified to be a promising prognostic biomarker as an oncogene in BLCA. It was also found that POLE2 exerts a promoting function by the PI3K/AKT signaling pathway in BLCA.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Qu G, Liu Z, Yang G, Xu Y, Xiang M, Tang C . Development of a prognostic index and screening of prognosis related genes based on an immunogenomic landscape analysis of bladder cancer. Aging (Albany NY). 2021; 13(8):12099-12112. PMC: 8109062. DOI: 10.18632/aging.202917. View

Lenis A, Lec P, Chamie K, Mshs M . Bladder Cancer: A Review. JAMA. 2020; 324(19):1980-1991. DOI: 10.1001/jama.2020.17598. View

Dy G, Gore J, Forouzanfar M, Naghavi M, Fitzmaurice C . Global Burden of Urologic Cancers, 1990-2013. Eur Urol. 2016; 71(3):437-446. DOI: 10.1016/j.eururo.2016.10.008. View

Sievert K, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M . Economic aspects of bladder cancer: what are the benefits and costs?. World J Urol. 2009; 27(3):295-300. PMC: 2694315. DOI: 10.1007/s00345-009-0395-z. View

Humphrey P, Moch H, Cubilla A, Ulbright T, Reuter V . The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016; 70(1):106-119. DOI: 10.1016/j.eururo.2016.02.028. View

Saginala K, Barsouk A, Aluru J, Rawla P, Padala S, Barsouk A . Epidemiology of Bladder Cancer. Med Sci (Basel). 2020; 8(1). PMC: 7151633. DOI: 10.3390/medsci8010015. View

Lerner S, Bajorin D, Dinney C, Efstathiou J, Groshen S, Hahn N . Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2016; 2(2):165-202. PMC: 4927845. DOI: 10.3233/BLC-160053. View

Bhattacharjee S, Sullivan M, Wynn R, Demagall A, Hendrix A, Sindhwani P . PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth. BMC Cancer. 2022; 22(1):312. PMC: 8944004. DOI: 10.1186/s12885-022-09376-9. View

10.

Cai Q, Wu Y, Guo Z, Gong R, Tang Y, Yang K . Urine BLCA-4 exerts potential role in detecting patients with bladder cancers: a pooled analysis of individual studies. Oncotarget. 2015; 6(35):37500-10. PMC: 4741944. DOI: 10.18632/oncotarget.6061. View

11.

Sexton W, Wiegand L, Correa J, Politis C, Dickinson S, Kang L . Bladder cancer: a review of non-muscle invasive disease. Cancer Control. 2010; 17(4):256-68. DOI: 10.1177/107327481001700406. View

12.

Narayan V, Vaughn D . Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer. Expert Opin Drug Metab Toxicol. 2015; 11(5):731-42. DOI: 10.1517/17425255.2015.1005600. View

13.

Reesink D, van de Garde E, Peters B, van der Nat P, Los M, Horenblas S . Treatment patterns and clinical outcomes of chemotherapy treatment in patients with muscle-invasive or metastatic bladder cancer in the Netherlands. Sci Rep. 2020; 10(1):15822. PMC: 7519076. DOI: 10.1038/s41598-020-72820-y. View

14.

Kaur J, Choi W, Geynisman D, Plimack E, Ghatalia P . Role of immunotherapy in localized muscle invasive urothelial cancer. Ther Adv Med Oncol. 2021; 13:17588359211045858. PMC: 8461126. DOI: 10.1177/17588359211045858. View

15.

Stenzl A, Cowan N, De Santis M, Kuczyk M, Merseburger A, Ribal M . Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol. 2011; 59(6):1009-18. DOI: 10.1016/j.eururo.2011.03.023. View

16.

Yang Z, Xu Y, Bi Y, Zhang N, Wang H, Xing T . Immune escape mechanisms and immunotherapy of urothelial bladder cancer. J Clin Transl Res. 2021; 7(4):485-500. PMC: 8445627. View

17.

Wolacewicz M, Hrynkiewicz R, Grywalska E, Suchojad T, Leksowski T, Rolinski J . Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives. Cancers (Basel). 2020; 12(5). PMC: 7281703. DOI: 10.3390/cancers12051181. View

18.

Zucali P, Cordua N, DAntonio F, Borea F, Perrino M, DE Vincenzo F . Current Perspectives on Immunotherapy in the Peri-Operative Setting of Muscle-Infiltrating Bladder Cancer. Front Oncol. 2020; 10:568279. PMC: 7609911. DOI: 10.3389/fonc.2020.568279. View

19.

Chi M, Liu J, Mei C, Shi Y, Liu N, Jiang X . TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer. J Exp Clin Cancer Res. 2022; 41(1):175. PMC: 9112458. DOI: 10.1186/s13046-022-02377-3. View

20.

de Jong J, Liu Y, Robertson A, Seiler R, Groeneveld C, van der Heijden M . Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis. Genome Med. 2019; 11(1):60. PMC: 6796434. DOI: 10.1186/s13073-019-0669-z. View